118 related articles for article (PubMed ID: 22584333)
1. [Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy].
Ito S; Ogawa Y; Harada H; Yamaguchi T; Munakata K
Gan To Kagaku Ryoho; 2012 May; 39(5):793-6. PubMed ID: 22584333
[TBL] [Abstract][Full Text] [Related]
2. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
Omlin A; D'Addario G; Gillessen S; Cerny T; von Hessling A; Früh M
Lung Cancer; 2009 Sep; 65(3):383-4. PubMed ID: 19375814
[TBL] [Abstract][Full Text] [Related]
3. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Zhang RX; Cai DY; Hong TT; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):147-51. PubMed ID: 22780936
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
8. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
9. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study.
Jalal S; Ansari R; Govindan R; Bhatia S; Bruetman D; Fisher W; Masters G; White A; Stover D; Yu M; Hanna N;
J Thorac Oncol; 2009 Jan; 4(1):93-6. PubMed ID: 19096313
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
Hattori Y; Iwasaku M; Satouchi M; Nishiyama A; Korogi Y; Otsuka K; Fujita S; Katakami N; Mori M; Nishino K; Morita S; Negoro S
Jpn J Clin Oncol; 2013 Dec; 43(12):1184-9. PubMed ID: 24168805
[TBL] [Abstract][Full Text] [Related]
12. [A case of lung cancer resistant to pemetrexed responding to S-1 monotherapy].
Oyamada Y; Maeshima A; Takeuchi K; Kato R
Gan To Kagaku Ryoho; 2013 Jun; 40(6):781-4. PubMed ID: 23863658
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Zhang RX; Cai DY; Wu XH; Hua D
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with pemetrexed in a patient with mucinous bronchioloalveolar carcinoma: long-term response duration with mild toxicity.
Okuda C; Kim YH; Takeuchi K; Togashi Y; Masago K; Sakamori Y; Mio T; Mishima M
J Thorac Oncol; 2011 Mar; 6(3):641-2. PubMed ID: 21317746
[No Abstract] [Full Text] [Related]
15. [A case of adenocarcinoma of the lung with malignant pleural effusion in elderly patient treated effectively by pemetrexed and carboplatin].
Tada A; Sakaguchi K; Kobayashi M; Kagoshima T; Yamazaki Y; Kamisawa O
Gan To Kagaku Ryoho; 2012 Mar; 39(3):425-7. PubMed ID: 22421772
[TBL] [Abstract][Full Text] [Related]
16. Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.
Mou W; Liu Z; Luo Y; Zou M; Ren C; Zhang C; Wen X; Wang Y; Tian Y
Med Oncol; 2014 Sep; 31(9):59. PubMed ID: 25119500
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Sun JM; Lee KH; Kim SW; Lee DH; Min YJ; Yun HJ; Kim HK; Song HS; Kim YH; Kim BS; Hwang IG; Lee K; Jo SJ; Lee JW; Ahn JS; Park K; Ahn MJ;
Cancer; 2012 Dec; 118(24):6234-42. PubMed ID: 22674612
[TBL] [Abstract][Full Text] [Related]
18. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.
Hainsworth JD; Cebotaru CL; Kanarev V; Ciuleanu TE; Damyanov D; Stella P; Ganchev H; Pover G; Morris C; Tzekova V
J Thorac Oncol; 2010 Oct; 5(10):1630-6. PubMed ID: 20802351
[TBL] [Abstract][Full Text] [Related]
19. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.
Bailon O; Chouahnia K; Augier A; Bouillet T; Billot S; Coman I; Ursu R; Belin C; Zelek L; Des Guetz G; Levy C; Carpentier AF; Morere JF
Neuro Oncol; 2012 Apr; 14(4):491-5. PubMed ID: 22362813
[TBL] [Abstract][Full Text] [Related]
20. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
Grønberg BH; Bremnes RM; Aasebø U; Brunsvig P; Fløtten O; Amundsen T; von Plessen C; Wang M; Sundstrøm S;
Lung Cancer; 2009 Jan; 63(1):88-93. PubMed ID: 18538889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
